At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
sildenafil +1 moredrug
Likely dose
sildenafil 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Local, Multi-Centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For One Hundred Twelve Weeks / Prior To Reimbursement And Availability For Patients In Poland.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jul 24, 2009·Updated Feb 1, 2021
In Brief
An observational study evaluating sildenafil for Pulmonary Hypertension. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland. Only safety and tolerability data will be collected in these patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesPoland
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionMar 2009
First PostedJul 2009
TodayJul 2026
First PostedJul 24, 2009
Enrollment StartJun 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.9 years ago
Interventions
sildenafildrug
tablets, 20mg, TID, 112 weeks at the maximum
sildenafildrug
tablets, 20mg x 4 (80mg), TID, approximately 70 weeks